Statistics from Altmetric.com
Recently, this journal published a paper from Marr et al 1 concerning multi-drug intra-arterial chemotherapy (IAC) for intraocular retinoblastoma. In many centres IAC has quickly garnered exciting interest, emerging as a promising, highly effective alternative for globe conserving treatment.2–4 In our institution, IAC with melphalan (IACM) has been performed since June 2008, and topotecan was added in June 2011. Fifty-nine patients have at least 1 year follow-up. Here we report our results obtained with IACM.
Forty-seven patients (table 1) for a total of 52 eyes with 22 newly diagnosed intraocular retinoblastomas (ND-RTBs) and 30 intraocular retinoblastomas after partial remission and/or relapses after other therapies (PR/R-RTBs) underwent IACM after a multidisciplinary group approval.5 The range of follow-up time is 19–61 months (median 39.6 months).
Competing interests None.
Ethics approval Ethics Committee of Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.